Brief: Advicenne Says EMA Granted ADV7103 Orphan Drug Designation

Advicenne SA

18/12/2019 17:00

Dec 18 (Reuters) - Advicenne SA  ADVIC.PA :
    * ANNOUNCED THAT ITS LEAD DRUG CANDIDATE, ADV7103, HAS BEEN
GRANTED ORPHAN DRUG DESIGNATION BY EUROPEAN MEDICINES AGENCY
(EMA) FOR TREATMENT OF CYSTINURIA IN EUROPE.
    * ADV7103 AND IS CURRENTLY IN PHASE III TRIALS FOR THIS
INDICATION
IN UNITED STATES AND CANADA

Source text for Eikon:  ID:nBw1PWhnXa 
Further company coverage:  ADVIC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))